"Lung Cancer - Pipeline Review, 2015" is now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Fri Nov 06 2015

GlobalData's Medical Devices sector report, "Lung Cancer - Pipeline Review, 2015" provides an overview of Lung Cancer diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Full Report Details at
- http://www.fastmr.com/prod/1063057_lung_cancer_pipeline_2015.aspx?afid=302

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Report Scope

* Extensive coverage of the Lung Cancer diagnostic tests under development
* The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
* The report reviews the major players involved in the development of Lung Cancer diagnostic tests and list all their pipeline projects
* The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
* The report provides key clinical trial data of ongoing trials specific to pipeline products
* Recent developments in the segment / industry

Reasons to Get this Report

The report enables you to -

* Formulate significant competitor information, analysis, and insights to improve R&D strategies
* Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
* Identify and understand important and diverse types of Lung Cancer diagnostic tests under development
* Develop market-entry and market expansion strategies
* Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
* In-depth analysis of the product's current stage of development, territory and estimated launch date

Companies Mentioned in this Report: A&G Pharmaceutical, Inc., Abbott Diagnostics, Abcodia Ltd., Aberystwyth University, Advanced Marker Discovery, S.L., Advpharma Inc., Almac Diagnostics Limited, Armune BioScience, Inc., Biocept, Inc., Biodesix Inc., BioMark Diagnostics Inc., BioMark Technologies Inc., BioMarker Strategies, LLC, BioNTech AG, BioSystems International, BioTime, Inc., Boise State University, Cancer Research Technology Limited, Cangen Biotechnologies, Inc., Celera Corporation, Cellanyx Diagnostics, Inc., CellMax Life, CeMines, Inc., Cepheid, Ceres Nanosciences, Inc., Cernostics Inc., ChemImage Corporation, Chronix Biomedical, Inc., Clarient, Inc., Courtagen Life Sciences, Inc., Dako A/S, Dartmouth College, DiagnoCure Inc., EDP Biotech Corporation, Emory University, Epigenomics AG, Eventus Diagnostics, Inc., Exact Sciences Corporation, Exiqon A/S, Exosomics Siena SpA, Fina Biotech, Fluxion Biosciences, Inc., Forschungszentrum Borstel, Gene Express, Inc., GeneCentric Diagnostics, Inc., Genentech, Inc., GenomicTree, Inc., GILUPI Nanomedizin, Global Discovery Biosciences, GlycoZym, HTG Molecular Diagnostics, Inc., ImmunoCellular Therapeutics, Ltd., Insight Genetics, Inc., Institut National de la Sante et de la Recherche Medicale, InterGenetics Incorporated, IV Diagnostics, Inc., Laboratorios SALVAT S.A., Louisville Bioscience, Inc., Mayo Clinic, MDNA Life Sciences, Inc., MDxHealth SA, Medical Prognosis Institute A/S, MEDITE Cancer Diagnostics, Inc., Memory Dx, LLC, Metabolon, Inc., Metanomics Health GmbH, MetaStat, Inc., Milagen, Inc., MolecularMD, Corp., Nanopore Diagnostics, LLC, Neogenix Oncology, Inc., NEOMICS Co., Ltd., Novel Bio-spectrum Technologies, Inc., Nuvera Biosciences, Inc., Oncolome Diagnostics Inc., Onconome, Inc., OPKO Health, Inc., Orion Genomics LLC, OTraces Inc., Oxford Gene Technology Limited, PeriRx LLC, PleX Diagnostics, Precision Biologics, Inc., PreMD Inc., Proplex Technologies, Llc, Proteome Sciences Plc, Proteomika, Quest Diagnostics Incorporated, RiboMed Biotechnologies, Inc., Roche Diagnostics International Ltd., Rosetta Genomics, Ltd., Roswell Park Cancer Institute, Siemens Healthcare Diagnostics Inc., Sienna Cancer Diagnostics Ltd, Sividon Diagnostics GmbH, SomaLogic, Inc., Southern Illinois University Carbondale, Syndax Pharmaceuticals, Inc., The Wistar Institute, Todos Medical, Transgene SA, Trinity College Dublin, University of Chicago, University of Colorado, University of South Florida, University of Strathclyde, US Biomarkers, Inc., Ventana Medical Systems, Inc., Veracyte, Inc., Vigilant Biosciences, Inc., Viomics Inc., VisionGate, Inc., Vitatex Inc., VolitionRX Ltd., XEPTAGEN SpA, Zetiq Technologies Ltd.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Acquired Gene or Chromosome Alterations - Pipeline Review, 2015
- Abbott Diagnostics - Product Pipeline Analysis, 2015 Update
- Pancreatic Cancer - Pipeline Review, 2015
- Ovarian Cancer - Pipeline Review, 2015
- Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »